Thymosin Beta-4
Profil Związku

Thymosin Beta-4

Actin-sequestering, tissue repair & angiogenesis

Znany również jako: Tβ4 · TB4 · TMSB4X · thymosin β4

Photo by Chokniti Khongchum / Pexels

Chemistry data
Class
naturally occurring 43-amino acid actin-sequestering peptide
Molecular weight
4921 g/mol
Sequence
SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 amino acids, acetylated N-terminus)
Half-life
estimated 2–6 hours in circulation (rapidly distributed to tissues)
Routes
ophthalmic (eye drops — RGN-259 clinical formulation) · topical · subcutaneous · intravenous
Studied doses
ophthalmic 0.1% RGN-259 solution, applied as eye drops (clinical trial formulation) · topical varies by study; typically applied directly to wound site in preclinical models

Status Regulacyjny

Stany Zjednoczone
investigational_new_drug
Unia Europejska
investigational
Wielka Brytania
investigational

Jak to działa

Wyniki badań

Kontekst dawkowania

  • Drogi Podania
    ophthalmic
    Zakres
    0.1% RGN-259 solution, applied as eye drops (clinical trial formulation)

    Phase 3 clinical trials for neurotrophic keratopathy and dry eye disease

  • Drogi Podania
    topical
    Zakres
    varies by study; typically applied directly to wound site in preclinical models

    animal wound-healing studies

🧮 Reconstitution Calculator

Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.

Open Calculator →

Efekty uboczne: kontekst badań

  • generally well-tolerated in clinical trials (ophthalmic formulation)
  • mild ocular discomfort reported in some RGN-259 trial participants (self-resolving)
  • no serious adverse events attributed to Tβ4 in published Phase 3 data

Pełne podsumowanie badań wkrótce. Tymczasem zajrzyj do danych naukowych i referencji PubMed powyżej.

Powiązane Strony